The provincial health minister announced patients diagnosed with cancer will have better access to care. Weekend and evening cancer treatments are now being made available.
Category: Hematology
Gleevec Keeps a Leukemia in Check for More Than a Decade: Study
… found. In the early days, Hochhaus explained, there was concern that Gleevec could eventually raise the odds of other health conditions, such as heart disease. He and his colleagues report the findings in the March 9 New England Journal of Medicine …
Colorectal cancer rates rise among young U.S. adults
A couple of years ago his doctor suggested a colonoscopy. But because Devries was far younger than the recommended age for a first colonoscopy – 50 for those with no family history, 45 for African-Americans – his insurer said it probably wouldn’t pay, and if it did, his high-deductible plan would leave him footing most of the bill.
Connor’s Heroes nonprofit hopes to encourage pediatric cancer research in Richmond
Thank you for reading 10 free articles on our site. You can come back at the end of your 30-day period for another 10 free articles, or you can purchase a subscription and continue to enjoy valuable local news and information.
First Cancer Patient Treated In Phase I/II Trial of ApoGrafta
Cellect Biotechnology Ltd. , a developer of stem cells selection technology, today announces that it has treated the first blood cancer patient in the recently initiated Phase I/II trial of its stem cell technology ApoGraftTM. The trial is intended to assess the Cellect ApoGraftTM process which is designed to prevent Graft-versus-Host Disease , a common complication associated with stem cell transplant in which the transplanted immune cells attack the recipient’s body cells and organs.
Genmab Appoints Judith Klimovsky, MD, as Chief Development Officer
Genmab A/S announced today the appointment of Judith Klimovsky, MD, as Executive Vice President and Chief Development Officer . Dr. Klimovsky will lead the company’s global product development activities and will join the Executive team of Chief Executive Officer, Dr. Jan van de Winkel and Chief Financial Officer, David Eatwell.
Hepatitis B can be acquired at age 5′
Members of the Ghana Association for the Study of Liver and Digestive Diseases are advocating a nationwide campaign to increase public awareness on Hepatitis. Interacting with TV3 after a one-day training workshop for health experts on the hepatitis B, the national president of the association, Dr Mary Yeboah Afihene, said only a few of the estimated 10-15 percent of Ghanaian adults with chronic hepatitis are aware of their condition.
Therapeutic Apheresis & Donor Apheresis Market Global Analysis 2024
… and Opportunities The growth of the global apheresis market can be attributed to the growing awareness regarding good health among consumers worldwide. The rising concerns among consumers regarding the prevalence several anomalies have impelled them …
Prevalence of atrial fibrillation in haemodialysis patients higher than previously thought
Atrial fibrillation, which is the most common cardiac arrhythmia, is an important risk factor for strokes. A multi-centre study led by MedUni Vienna shows that the prevalence of atrial fibrillation in haemodialysis patients in Vienna is significantly higher than previously thought.
Local nonprofit makes $100,000 commitment to Advocate Children’s Hospital
Andrew Smialek was just 14 years old when he was diagnosed with Hodgkin lymphoma. He spent his high school years and first year of college undergoing chemotherapy, as well as stem cell and bone marrow transplants.
Catalyst Biosciences Completes Manufacturing Agreements for its Novel …
Catalyst Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced it has secured all rights to the manufacturing process for marzeptacog alfa from Wyeth LLC, a wholly-owned subsidiary of Pfizer. Marzeptacog alfa is a next-generation Factor VIIa product that was designed to allow for the effective, long-term, subcutaneous prophylaxis in hemophilia patients with inhibitors.